Quantcast

Latest American Association for Cancer Research Stories

2013-10-21 13:17:16

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...

2013-10-21 13:15:33

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity,...

2013-10-21 10:09:54

The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung...

2013-10-21 10:08:34

Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. Mutant forms of the protein KRAS are found in approximately 30 percent of all cancers. They are responsible for many of the hallmarks of these...

2013-10-15 11:17:03

An optical imaging technique that measures metabolic activity in cancer cells can accurately differentiate breast cancer subtypes, and it can detect responses to treatment as early as two days after therapy administration, according to a study published in Cancer Research, a journal of the American Association for Cancer Research. "The process of targeted drug development requires assays that measure drug target engagement and predict the response (or lack thereof) to treatment," said Alex...

2013-10-09 23:03:40

Charles J. Sherr, M.D., Ph.D., to receive the Prize for Scientific Excellence in Medicine by the American-Italian Cancer Foundation Memphis, Tenn. (PRWEB) October 09, 2013 Charles J. Sherr, M.D., Ph.D., chair of the St. Jude Children’s Research Hospital Department of Tumor Cell Biology and a Howard Hughes Medical Institute Investigator, has been selected to receive the 2013 Prize for Scientific Excellence in Medicine by the American-Italian Cancer Foundation. The Prize for Scientific...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.